Ivy Chung et al., 2020: Chung et al. report that micelle- or nanoparticle-formulated fenbendazole and albendazole prolong survival in mice with prostate cancer metastases, with albendazole outlasting paclitaxel.
The enhanced forms of fenbendazole and albendazole significantly prolonged survival in mice bearing metastases, and albendazole-treated mice displayed significantly longer median survival times than paclitaxel-treated mice.
Ivy Chung et al., 2020: Chung et al. report that micelle- or nanoparticle-formulated fenbendazole and albendazole prolong survival in mice with prostate cancer metastases, with albendazole outlasting paclitaxel. Study type: mouse experimental metastasis models (lung and bone) plus subcutaneous xenografts. N: not stated in the abstract. Country: USA (Boston Children's Hospital / Harvard). Dose: 100 mg/kg intraperitoneally three times a week (free drug), with formulated versions used for the survival arms. Funder: not stated in the record. Declared conflicts: patent application 13/320,635 filed by three of the authors. Comparator: unformulated drug, paclitaxel, and the other four hit compounds. CORRECTION: the survival comparison in the abstract is albendazole versus paclitaxel, not albendazole versus fenbendazole; the paper also states that 'these drugs effectively targeted taxane-resistant tumors and bone metastases'. The earlier draft of this row had the comparison wrong and it was fixed against the fetched abstract text. Also filed as FBC-26 (claims C5, C7). Study type: animal.
